title: [High-dose cytosine arabinoside and L-asparaginase in the treatment of refractory or recurrent acute non-lymphoblastic leukemia].
authors: M A
authors: MA
authors: Sanz
authors: D
authors: D
authors: Borrego
authors: G
authors: G
authors: Martín-Aragonés
authors: J A
authors: JA
authors: Martínez
authors: I
authors: I
authors: Lorenzo
authors: G
authors: G
authors: Sanz
authors: M J
authors: MJ
authors: Sayas
authors: I
authors: I
authors: Jarque
authors: E
authors: E
authors: Pastor
authors: J
authors: J
authors: Rafecas
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012074:Remission Induction
chemical_list: D003561:Cytarabine; D001215:Asparaginase
vernacular_title: Arabinósido de citosina a altas dosis (Ara-C-AD) y L-asparaginasa (L-ASP) en el tratamiento de la leucemia aguda no linfoblástica refractaria o en recidiva.